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ABSTRACT 
Marcetia taxifolia is a neotropical plant present in South America and it has been evaluated in several biological 
models due to the presence of active metabolites. Nevertheless, there is a limited quantity of studies related to 
the antiviral activity of the compounds present in this genus. In our work, the antiviral effect of the compounds 
isolated from the aerial parts of Marcetia taxifolia was evaluated against Hepatitis B virus (HBV), Herpes Sim-
plex Virus type 1 (HSV-1), and Poliovirus type 1 (PV-1). The cytopathic effect and viral quantification by qPCR 
were determined as indicative of antiviral activity. Our data show that myricetin rhamnoside (MyrG), myricetin-
3-α-O-ramnosil (1→6)-α-galactoside (MyrGG), 5,3'-dihydroxy-3,6,7,8,4’-pentamethoxyflavone (PMF), 5-
hydroxy-3,6,7,3',4'pentamethoxyflavone (PMF-OH) had antiviral activity without cytotoxic effects. The meth-
oxyflavones PMF and PMF-OH were the most active compounds, showing an antiviral effect against all the 
evaluated viruses. Computational studies showed that these compounds could interact with the Reverse Tran-
scriptase. Altogether, these results suggest that the flavonoids (related to myricetin and methoxyflavones) are the 
main antiviral compounds present in the aerial parts of Marcetia taxifolia. Furthermore, our results showed that 
the methoxyflavones have a broad antiviral activity, which represents an opportunity to evaluate these flavonoids 
as lead molecules to develop new antiviral compounds. 
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INTRODUCTION 
Emergence, resistance and spreading of 
viral strains promote research for new antivi-
ral drugs. In fact, several biological com-
pounds are found in plants and some of these 
plant extracts have shown broad antiviral 
properties. These inhibitory effects could be 
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related to blocking main viral enzymes di-
rectly or in some cases, to be modulating a 
cellular pathway (Arena et al., 2004; Jassim 
and Naji, 2003; Sharma et al., 2009). These 
molecular mechanisms are similar to the 
drugs used in antiviral therapy: direct-acting 
antiviral and drugs that block a host cellular 
process avoiding viral replication (Ortega et 
al., 2013). 
Marcetia is a Neotropical genus distrib-
uted from Venezuela to Uruguay (Berry and 
Luckana, 2001). Baptista et al. (2016) de-
scribed for the first time the compounds pre-
sent in the aerial parts of Marcetia taxifolia. 
These compounds are: marcetol (1), 5-α-
cholestan-3-β-ol (2), 5-α-cholestan-7-en3-β-
ol (3), 24,25-dehydropollinastanol (4), lupa-
12,20(29)-dien-3-ol (5), 5,3'- dihydroxy-
3,6,7,8,4’-pentamethoxyflavone (6), 5-
hydroxy-3,6,7,3',4'pentamethoxyflavone (7), 
myricetrine (8) and myricetin-3-α-O-
ramnosil (1→6)-α-galactoside (9). Previous 
reports have shown that these methoxyfla-
vones and myricetrine have antiviral activity 
against HIV-1 (Ortega et al., 2017 a,b). Ad-
ditionally, Leite et al. have reported the anti-
bacterial and antifungal activities of Mar-
cetia taxifolia extract. These activities are 
principally associated with polymethoxylat-
ed flavonoids (Leite et al., 2012). However, 
the antiviral activity of these compounds has 
been scarcely evaluated. Thus, in this study 
the compounds obtained from the aerial parts 
of Marcetia taxifolia were evaluated against 
three different viral families of public health 
concern: Hepatitis B virus (HBV), Herpes 
simplex virus (HSV) and Poliovirus (PV). 
HBV affects around 240 million people 
worldwide and is related to hepatic cirrhosis 
and hepatocellular carcinoma (WHO, 2019). 
HSV may produce oral or genital lesion de-
pending on the virus type (HSV-1 and HSV-
2 respectively) (Whitley and Baines, 2018) 
and Poliovirus is associated with paralysis in 
unvaccinated children (Menant and Gande-
via, 2018). These viruses exhibit many dif-
ferences in the replicative cycle. Therefore, 
the aim of this study was to evaluate the an-
tiviral activity of compounds isolated from 
Marcetia taxifolia against these different vi-
ral families. 
 
MATERIAL AND METHODS 
Cell culture, viruses, and compounds 
HepG2.2.15 cells were kindly donated by 
Dr. Isabelle Chemin (Team leader Hepato-
carcinogenesis and viral infections) from 
INSERM, France. These cells were grown in 
RPMI medium supplemented with 10 % fetal 
bovine serum (Gibco), 100 IU/mL penicillin 
G, 100 µg/mL streptomycin, 0.25 µg/mL 
amphotericin B and 200 µg/mL G418 and 
Vero cells in Eagle medium supplemented 
with 10 % fetal bovine serum (Gibco), 100 
IU/ml penicillin G, 100 µg/mL streptomycin 
at 37 °C under 5 % CO2 in a CO2 incubator. 
Herpes simplex type 1 F strain (HSV-1), po-
liovirus type 1 Sabin strain (PV-1) of viral 
repository stocks from “Cátedra Virología, 
Facultad de Farmacia y Bioquímica, UBA, 
Argentina”. 
The Marcetia taxifolia (A.St.-Hil.) DC., 
plant collection, verification, and compound 
isolation were previously described (Baptista 
et al., 2016). The Marcetia taxifolia (A.St.-
Hil.) DC. (Melastomataceae) was collected 
in the Amazonanian state in Venezuela. The 
chemical constituents were separated 
through organic extraction, further isolation 
was developed by chromatographic tech-
niques and the compounds were character-
ized using spectroscopic and spectrometric 
methods. 
 
Cytotoxicity assay 
The cytotoxicity assays were determined 
by the MTT method (Mosmann, 1983). Also, 
the cells were seeded in 96-wells plate at a 
density of 1.5 x 104 cells/well. The next day, 
different concentrations of the flavonoid 
compounds were added to the cells and 24 h 
later, the cell viability was evaluated using 
the MTT (ThermoFisher, USA) cell prolifer-
ation assay as previously described (Ortega 
et al., 2017a).  
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HBV antiviral assay 
HepG2.2.15 constitutively produces 
HBV particles and is broadly used to evalu-
ate the antiviral activity (Sells et al., 1988). 
The HBV production was quantified through 
a real-time PCR methodology, using as tar-
get the X gene. The sequence of specific 
primers was forwarded-1608-1627: ATG 
GAG ACC ACC GTG AAC GC and re-
versed-1887-1868 AGG CAC AGC TTG 
GTG GCT TG. The amplification product 
was of approximately 260 bp.  Briefly, 24 h 
prior to the antiviral assay, the cells were 
seeded at a density of 1.2 x 104 cells / well 
for each condition. The cells were incubated 
with “Infection medium” (RPMI with 2 % 
FBS and 1 % DMSO) (Quintero et al., 2011) 
with and without the compounds at the de-
scribed concentrations. After 72 h, the medi-
um and the compounds were refreshed by 
replacing them and incubated by 72 h. The 
supernatant was collected and viral DNA ex-
tracted using High Pure Viral Nucleic Acid 
Kit (Roche Life Science, Germany). The de-
velopment of qPCR was done on Applied 
Biosystems 7300 by using a Sybr green 
commercial kit (Luna® Universal qPCR, Kit 
NEB Co. USA). The amplification condi-
tions were the following: 3 min at 95 °C, 40 
cycles of 15 sec. at 95 °C, 30 sec. at 61 °C 
and 30 sec. at 72 °C. The viral inhibition rel-
ative to control ( %) was calculated. Statisti-
cal analyses of at least three independent ex-
periments were performed.  
 
Herpes virus and polio antiviral assay 
To determine the antiviral activity 
against Herpes and Polio, a plaque reduction 
assay, on 24 well culture plates was per-
formed. The Vero cells were infected with 
100 plaque forming units (PFU) of HSV-1 or 
PV-1. After 60 min adsorption at 37 °C and 
5 % CO2 the virus was removed. Then, the 
monolayers were washed twice with PBS 
and overlaid with plaque medium (0.5 % 
Methylcellulose). Next, the compounds were 
added at different concentrations in each 
well and incubated by 24 or 48 h for PV-1 
and HSV-1 respectively. Finally, cells were 
fixed with 10 % formalin and stained with 
0.4 % crystal violet. Viral infection, cellular 
morphology, and cytotoxic controls in each 
assay were all performed.  
 
3D model building and refinement 
Homology modeling 
A homology model of the Hepatitis B vi-
rus Reverse Transcriptase (HBV-RT) was 
generated by using the crystallographic 
structure of HIV-1 Reverse Transcriptase 
(HIV-1-RT) (PDB 3V81) as the template 
(Daga et al., 2010; Das et al., 2012). The ini-
tial model was obtained with the SWISS-
MODEL modeling server (Arnold et al., 
2006) and the tools of DeepView/Swiss-
PdbViewer 4.01 software (Guex and Peitsch, 
1997). In this model, hydrogen atoms were 
added, and the partial charges were assigned 
for energy refinement. After that, the protein 
model was embedded in a 100 Å water box. 
Then, energy minimization preserving the 
enzyme folding and optimizing the relative 
position between the water molecules and 
the fixed backbone atoms was performed. 
The obtained system underwent a one nano-
second (ns) molecular dynamic (MD) simu-
lation with the following characteristics: (a) 
Periodic Boundary Conditions (PBC) were 
introduced to stabilize the simulation space; 
(b) the long-range electrostatic potential was 
treated by the Particle Mesh Ewald summa-
tion method (PME) (Toukmaji et al., 2000); 
(c) Newton’s equation using the r-RESPA 
method (Masella, 2006) (every 4 femtosec-
onds (fs) for long-range electrostatic forces, 
2 fs for short-range non-bonded forces, and 1 
fs for bonded forces) was integrated; (d) the 
temperature was maintained 300 ± 5 K by 
means of Langevin’s algorithm (Izaguirre et 
al., 2012); (e) Lennard-Jones (L-J) interac-
tions were calculated with a cut-off of 14 Å, 
the switching distance was 10 Å, and the 
non-bonded pair list distance was 14 Å; (f) a 
frame every 5 pico seconds (ps) was stored, 
yielding 2000 frames; (g) constraints with a 
force constant of 1000kcal/mol/Å2 were ap-
plied to the backbone atoms (N, Ca, C, O) 
and gradually decreased during the simula-
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tion. The simulations were carried out in 
three phases: an initial period of heating 
from zero to 300 K over nine ps; an equili-
bration MD simulation of 0.1 ns, and moni-
tored MD phase of simulation of one ns. The 
lowest energy frame of the MD simulation 
was further minimized and represented in the 
final structure. MD simulations described in 
the study were performed with NAMD 2.8 
(Phillips et al., 2005)/Vega ZZ 3.1.0.21, us-
ing the CHARMM force field (Va-
nommeslaeghe et al., 2010) and the Gastei-
ger charges. All reported minimizations were 
performed using the conjugate gradient algo-
rithm until a root-median square (rms) gradi-
ent was smaller than 0.01 kcal/mol/Å.  The 
final model validation was carried out with 
ProSA (Wiederstein and Sippl, 2007) and 
PROCHECK programs (Laskowski et al., 
1993). 
 
Molecular docking with HBV-RT 
The 3D structure of each inhibitor was 
obtained from the PubChem database (Kim 
et al., 2016) or generated by parent structure 
modification with VegaZZ 3.1.0.21 (Pedretti 
et al., 2004). The molecular docking was 
performed with AutoDock 4/VegaZZ 
3.1.0.21 and 30 runs conducted for each 
compound. Sampling in a cube of 10 Å sides 
around the ligand was carried out. The re-
sults were prioritized according to the pre-
dicted free energy of binding. Then the final 
complexes, keeping the backbone atoms of 
the protein fixed and improving the mutual 
adaptability between ligand and enzyme 
were minimized. 
 
RESULTS  
The antiviral activity of the compounds 
isolated from the aerial parts of M. taxifolia 
in in vitro models of HBV, HSV-1, and PV-1 
was assayed. Table 1 summarizes the results 
for cytotoxicity and viral inhibition for the 
evaluated compounds. As indicated in this 
table, only: myricetin rhamnoside (MyrG), 
myricetine-3α-O-rhamnosyl (1→6)-α-galac-
toside (MyrGG), 5,3'-dihydroxy-3,6,7,8,4'-
pentamethoxyflavone (PMF) and 5-hydroxy-
3,6,7,3',4'-pentamethoxyflavone (PMF-OH), 
were active against at least one of the evalu-
ated viruses. Additionally, these compounds 
showed a scarce or non-cytotoxic effect. 
 
Table 1: Cytotoxic concentration and Inhibitory concentration of the tested compounds 
Compound CC5024h 
(µM) 
HepGa 
and 
Vero 
CC50144h’
(µM) 
HepG2a 
EC50 (µM) 
HBV 
SI
HBV 
EC50
(µM) 
PV-1 
SI 
PV-1 
EC50 
(µM) 
HSV-1 
SI 
HSV-1 
Myricetin  
rhamnoside (MyrG) 
>100 >100 0.015±0.0008 6667 NA - NA - 
myricetin-3-α-O-
ramnosil (1→6)-α-
galactoside (MyrGG) 
>100 >100 12±0.59 8,3 NA - NA - 
5,3'-dihydroxy-3,6,7,8,4’-
pentamethoxyflavone 
(PMF) 
>100 10±0.1 0.001±0.0005 10000 1±0.05 100 6.8±0.
2 
14.7 
5-hydroxy-3,6,7,3',4'-
pentamethoxyflavone 
(PMF-OH) 
>100 10±0.58 0.098±0.0001 102 1.1±0.03 90.9 5.9±0.
1 
16.9 
Marcetol >100 >100 NA - NA - NA - 
5-α-cholestan-3-β-ol >100 >100 NA - NA - NA - 
5-α-cholestan-7-en3-β-
ol 
>100 >100 NA - >10 - NA - 
24,25-
dehydropollinastanol 
>100 >100 NA - NA - NA - 
Upa-12,20(29)- 
dien-3-ol 
>100 >100 NA - NA - NA - 
a HepG2.2.15. NA: non-active 
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Antiviral activity on HSV-1 and PV-1 mod-
els 
The antiviral activity of each compound 
against Polio-1 and HSV-1 was assayed. The 
myricetin related compounds did not show 
antiviral activity against these viruses. How-
ever, methoxyflavones exhibited activity 
with an EC50 near to 1 µM against PV-1 
(Figure 1). An inhibitory effect of 90 % 
(PMF) and 60 % (PMF-OH) against HSV-1 
was observed at a concentration of 10 μM 
(Figure 1). 
 
Antiviral activity on the HBV model 
The selectivity index (SI) of the metho-
xyflavones (PMF and PMF-OH) against 
HBV was 10,000 and 102 respectively, with 
EC50 values of 0.001 µM for PMF and 0.098 
µM for PMF-OH. These compounds showed 
the highest antiviral activity against HBV 
(Figure 2A). Additionally, MyrG presents an 
SI of 6667 and an EC50= 0.015 µM while 
MyrGG showed an SI of 8.3 and EC50= 12 
µM (Figure 2B). 
Previous reports show that glycosylated 
flavonoids related to myricetin, as well as 
methoxyflavones, can inhibit the HIV-1-RT 
(Ortega et al., 2017b). Thus, the interaction 
of these compounds with the HBV reverse 
transcriptase (HBV-RT) as a potential target 
was evaluated in silico. To date, there is no 
experimental crystal structure of HBV-RT 
available. For this reason, a homology model 
of the HBV-RT was constructed by using the 
crystal structure of HIV-1-RT as a template. 
 
Homology modeling 
The alignment between HBV-RT and 
HIV-1-RT (UniProtKB O11885 and P03366) 
was performed using the structural alignment 
tool of Swiss-PdbViewer/DeepView (Figure 
3). The HIV-1-RT and HBV-RT share many 
of the residues involved in key protein-
ligand interactions (Daga et al., 2010). These 
include the YMDD motif and the catalytic 
triad of aspartic acid residues, Asp107, 
Asp229, Asp230. Some differences in the 
putative hydrophobic NNRTI-binding pocket 
were found. However, the insertion of 4 
amino acids in the HBV enzyme was the ma-
jor difference observed. Altogether, data 
suggest that HIV-1-RT and HBV-RT share 
enough structural and functional similarity to 
serve as a putative predictor for the interac-
tion with RT inhibitors. 
 
 
 
Figure 1: Antiviral activity of methoxyflavones against PV-1 and HSV-1 
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A 
 
B 
 
Figure 2: Antiviral activity of Marcetia taxifolia flavonoids against HBV. (A) methoxyflavones: PMF and 
PMF-OH, (B) Myricetin glycosides: MyrG and MyrGG 
 
 
A structural model of the HBV-RT using 
the SWISS-MODEL package was generated 
(Figure 4). Three main subdomains in the 
HBV-RT structure were identified: the fin-
ger, residues 1-49 and 90-172, the palm, res-
idues 50-89 and 173-267 and the thumb, res-
idues 268-351. Nevertheless, differences be-
tween the models were found (Figure 4). 
Homology comparison between HBV-RT 
model and HIV-1-RT template suggested a 
similar structural conformation with a root 
mean square deviation (rmsd) of 2.1 Å for 
the C? atoms (Table 2).  
The conformational differences related to 
the secondary structure between HIV-RT 
and HBV-RT were determined. The main 
HBV features were the elongations in 4 and 
5 residues occurring in the protein loops 
(Figure 4 B). The palm contains the poly-
merase active site and the non-nucleoside 
pocket located ~10 Å apart. No differences 
were observed around the three aspartate res-
idues of the catalytic triad: Asp107, Asp229, 
and Asp230, in HBV and corresponding in 
HIV-1 RT to Asp110, Asp185, and Asp186.
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Figure 3: Sequence alignment of HBV-RT and HIV-1-RT polymerases. Secondary structure prediction 
of HBV-RT. Predicted amino acid sequences of HBV-RT (O11885) and HIV-1-RT PDB code 3v81 
(P03366) were accordingly to Daga et al. (2010) conserved residues, which are highlighted with a red 
background.  
 
 
Docking at the NNRTI binding pocket 
Some flavonoids have been characterized 
as HIV-1-RT inhibitors. Furthermore, previ-
ous reports showed that these compounds, 
particularly myricetin and myricetin 3-
rhamnoside, could occupy the NNRTI pock-
et (Li et al., 2011; Ortega et al., 2017a). 
Thus, molecular docking study of glycosyl-
ated flavonoids (MyrG and MyrGG) and 
methoxyflavones (PMF and PMF-OH) into 
the NNRTI pocket on the HBV-RT model 
were carried out. Figure 5 shows the docking 
representation of the MyrG (A) and PMF (B) 
on the HBV-RT model, and Table 3 summa-
*
***
* ***
O11885 
P03366 
O11885 
P03366 
O11885 
P03366 
O11885 
P03366 
O11885 
P03366 
O11885 
P03366 
O11885 
P03366 
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rizes the docking scores for the ligands eval-
uated in this study. The compounds that best 
interact with the NNRTI pocket were the 
methoxyflavones. However, the best-docked 
compound was PMF-OH, with a binding en-
ergy of -5.59 kcal/mol. The compound PMF 
shows binding energy of -5.33 kcal/mol. 
However, the glycosylated flavonoids 
showed lower binding energy than methox-
yflavones. The best ranked binding energy 
was for MyrG with a binding energy of -4.61 
Kcal/mol. All these results are summarized 
in Table 3. 
 
 
Figure 4: Comparison between the homology model of HBV-RT and the crystal structure of HIV-1-RT. 
(A) Ribbon diagram of HBV-RT. Three subdomains are described:  Fingers (residues 1–49 and 90–
172, purple), palm (residues 50–89 and 173–267, blue), and thumb (residues 268–351, green). (B) 
HBV-RT (blue) and HIV-1-RT (yellow) are superimposed; regions showing significant differences are 
marked (*). Amino acids of the catalytic triad and Nevirapine are displayed in sticks.  
 
Figure 5: Docking results of MyrG (A) and PMF (B) over the HBV-RT model. 3D representations of 
the complex interactions categorized by hydrogen bonds (green dashed lines), π-stacks (pink-dashed 
lines). 
Asp229 
Thumb 
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Table 2: Structural comparison between the 
HBV-RT model and HIV-1-RT 
 HBV-RT HIV-1-RT 
PDB Code - 3V81 
Number of amino 
acid  
residues 
375 322 
Sequence  
identity with 
HBV_RT 
- 17 % 
RMSD 
Cversus 
HBV_RT 
0 
2.11 Å  
(300 C 
atoms) 
Total Area (Å2) 39576.3 33618.0 
Total Volume (Å3) 33829.1 28323.3 
%phi/psi 89.9 93.3 
Z-Score -3.7 - 3.7 
PDB = Protein data bank code; RMSD = root-mean-square 
deviation; C = -carbon 
aPhi and psi are torsion angle of all residues of the protein 
chain, %phi/psi: the phi-psi combination in favorable regions 
of the Ramachandran plot. 
 
 
DISCUSSION 
Plant-derived compounds represent a 
broad variety of chemical families. However, 
flavonoids have been the most widely stud-
ied as possible antivirals. Indeed, some of 
these compounds have been active against 
viruses such as HBV, Polio, and Herpes vi-
rus (Zhang et al., 2014; Eggers, 1985; Parvez 
et al., 2016; Huang et al., 2017). Marcetia 
genus plants are a source of flavonoids and 
have been barely studied. Thus, to determine 
the antiviral activity of the nine compounds 
isolated from the aerial parts of M. taxifolia, 
we selected three different in vitro models: 
HBV, HSV-1, and PV-1.  
The results showed that only the glyco-
sylated flavonoids related to myricetin and 
the methoxyflavones exhibited antiviral ac-
tivity. Myricetin related compounds and 
methoxyflavones were active against HBV 
(Figure 2). However, the most potent com-
pounds were the methoxyflavones (Figure 
2A). In our best knowledge, this is the first 
report that indicates the antiviral activity of 
these compounds on HBV. Interestingly, 
other flavonoids related to myricetin such as 
quercetin have exhibited an antiviral effect 
against HBV (Cheng et al., 2015). The 
methoxyflavones have been barely studied 
and there are just a few reports related to 
their antiviral activity. (Ortega et al., 2017a; 
Nagai et al., 1995; Eggers, 1985; De Meyer 
et al., 1991).  
Flavonoids and related compounds can 
interact with polymerases, especially with 
the reverse transcriptase (Kuete et al., 2010; 
Ono et al., 1990). Ortega et al. (2017a, b) de-
scribed that myricetin and methoxyflavones 
may act as non-nucleoside Reverse Tran-
scriptase inhibitors (NNRTI). Indeed, a Re-
verse Transcriptase is involved in the HBV 
replication cycle and this enzyme has a high 
similarity with the HIV-1-RT. The binding 
of MyrG and MyrGG on the reported NNR-
TI binding pocket was shown by molecular 
docking. Moreover, the binding energy was 
inversely proportional to glycosylation grade 
(Figure 5 and Table 3). The methoxyfla-
vones showed lower binding energies com-
pared to the glycosylated compounds. Addi-
tionally, these compounds produce more hy-
drogen bonds, which suggest a more stable 
interaction with the HBV-RT. These docking 
results are in concordance with the antiviral 
activities obtained in the in vitro model of 
HBV. Residues that consistently within 5 Å 
from docked ligands were Val87, Pro88, 
Asn89, Leu90, Ser92, Leu 93, Trp 103, 
Leu223, Ala224, Phe225, Val232, and 
Phe273. As shown, these results suggest the 
hydrophobic NNRTI pocket of HBV-RT as a 
potential target for new inhibitors.  
To determine the antiviral spectrum of 
these flavonoids, two additionally viral spe-
cies were selected as models. PV-1 (a single 
strain RNA virus) and HSV-1 (a DNA vi-
rus), which diverged from HBV in the repli-
cation mechanisms. Our data show that the 
glycosylated flavonoids did not have an in-
hibitory effect against Polio nor Herpes. 
These observations are in concordance with 
previous reports for these myricetin related 
compounds (Lin et al., 2000; Castrillo et al., 
1986). The methoxyflavones displayed a po-
tent effect against Polio and these results are 
in agreement with previous reports of similar
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Table 3: Docking results of the evaluated compounds using the HBV-RT model 
Mod ID EBa RT interactions Residues (H bonds) 
 
MyrG -4.61 
vdW:Trp103, Arg216, Leu223, Phe225, 
Val232,  Phe273 
Pi interactions: Pro88, Leu93 
Ala224, Pro88, Leu96 
 
MyrGG 
 
-2.65 
vdW: Val87, Phe85, Trp103, Leu223, Ala224, 
Phe225, Val232, Phe273 
Pi interactions: Lys84, Pro88, Leu93 
Ala86, Pro88 
PMF-OH -5.59 
vdW:  Asn89, Trp103, Leu223, Ser226, 
Tyr227, Asp230, Val231, Leu271, Asn272, 
Tyr276 
Pi interactions: Pro88, Leu93, Val232, Phe273, 
Ile278  
Leu90, Ser92, Ser105, 
Ala224, Phe225 
PMF -5.33 
vdW:  Phe85, Val87, Leu90, Ser92, Trp103, 
Leu223, Val232, Phe273 
Pi interactions: Pro88, Leu93, Phe225 
Asn89, Pro88, Arg216, 
Ala224 
MyrG: Mirecityn rhamnoside, MyrGG: myricetin-3-α-O-ramnosil (1→6)-α-galactoside, PMF: 5,3'-dihydroxy-3,6,7,8,4’-
pentamethoxyflavone, PMF-OH:5-hydroxy-3,6,7,3',4'pentamethoxyflavone   
EB free energy of binding (kcal/mol), vdW van der Waals interactions 
a Note that the more positive the free energy of binding, the less likely the probability interaction 
 
 
compounds versus this virus (Van Hoof et 
al., 1984; De Meyer et al., 1991). However, 
the effect of the methoxyflavones against 
HSV-1 (Figure 1) was modest compared to 
those observed against HBV (Figure 2a). Al-
together, these results showed that the meth-
oxyflavones are active against Polio, Herpes, 
and Hepatitis B. Additionally, as previously 
mentioned the methoxyflavones can inhibit 
influenza virus and HIV-1. These viruses do 
not share any replicative step thus; the broad 
range of antiviral activity of methoxyfla-
vones may suggest two possible inhibitory 
mechanisms: a) inhibiting viral polymerases 
by acting as non-selective inhibitors, or b) 
modulating a cellular process related to the 
viral replication cycle. Indeed, methoxyfla-
vones have been described as inhibitors of 
several cellular processes, such as the cell 
cycle, apoptosis, kinases pathway, 
NFKb/AKT pathway and others (Wudtiwai 
et al., 2011; Bhardwaj et al., 2016; Faqueti et 
al., 2016; Kim et al., 2014; Ma et al., 2015; 
Merlo et al., 2015; Shi et al., 2013; Nakao et 
al., 2011).  
In conclusion, the methoxyflavones 
showed antiviral activity against all the eval-
uated viruses, while the glycosylated flavo-
noids related to myricetin were active only 
on HBV. In the HBV model, the possible an-
tiviral mechanism could be related to HBV-
RT inhibition. On the other hand, the results 
obtained for PMF against HSV-1 and PV-1 
suggest that these compounds could have 
another mechanism related to a cellular pro-
cess modulation. However, additional phar-
macological studies to establish the target of 
the methoxyflavones and further evaluations 
of glycosylated flavonoids as RT inhibitors 
are needed. Altogether, these results show 
the potential of flavonoids as antiviral lead 
compounds.  
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